North America Migraine Drugs Market

North America Migraine Drugs Market Size (2024 to 2032)

The migraine drugs market size in North America is predicted to be valued at USD 1.61 billion in 2024 and USD 2.20 billion by 2032, growing at a CAGR of 3.98% from 2024 to 2032.

The growing incidence of migraine among the population of North America due to changing dietary habits and technology-based life is one of the major factors propelling the migraine drug market in this region. Migraine is one of the most common neurological diseases that affects most people in the US at any age group. Nearly one in five Americans suffer from this migraine. Migraine drug is used to treat or prevent migraine headaches and other conditions. As per the American Migraine Prevalence and Prevention, migraine affects nearly 12% of adults in the United States.

Women are more prone to this migraine disorder compared to men. Nearly one in five women in the United States suffers from this migraine disorder. In the United States, nearly 42 million Americans suffer from migraine, as per the research. Due to increasing family issues and the rules on the family, women make her think deeply and cause migraine due to overstress. Due to the increasing number of cases in this region yearly, women are taking care of themselves by preventing or reducing migraine disorders with drugs, which drives the North American migraine drugs market forward.

Growing awareness regarding the quality of migraine drugs for treating migraine and related problems further accelerates the growth rate of the migraine drug market in North America. In the recent past, most people have concentrated more on their health due to growing chronic diseases and infections. Most people have oral medication for this disorder compared to other forms. Most pharmaceutical companies focus on researching migraine drugs for fast relief from the migraine, which is a severe headache. These drug manufacturers are increasing development and clinical trials for the demand for migraine drugs in this region. Most researchers are going to conduct trials on antibodies. If the correct antibody drugs are taken by the migraine patient suffering from migraine due to a cold or any other reason, it gives a fast reaction and reduces the pain.

The growing number of advancements in the healthcare infrastructure of North American countries that support the diagnosis and treatment of migraine, the increasing number of awareness initiatives by healthcare organizations to improve knowledge levels of people around migraine and technological advancements are supporting the migraine drugs market in North America. Favorable reimbursement policies and the growing number of R&D activities by the market participants to innovate effective migraine drugs are further fuelling the growth rate of the North American market.

On the other hand, high costs associated with the advanced drugs, lack of regulatory approvals, and some of the side effects of the drug, such as visual disturbances, nausea, vomiting, dizziness, and sensitivity to light noises, are the factors restraining the market growth. Additionally, increasing alternative therapies for this migraine also hamper the market growth in this region.

This research report on the North American migraine drugs market has been segmented and sub-segmented into the following categories:

North America Migraine Drugs Market Analysis By Treatment

• Preventive
• Absorptive

The preventive segment is expected to capture the leading share of the North American migraine drugs market during the forecast period owing to the growing awareness among patients of migraine regarding preventive medications and the increasing prevalence of chronic migraine.

North America Migraine Drugs Market Analysis By Therapeutic Class

• Triptans
• Ergots
• Others

North America Migraine Drugs Market Analysis By Country

• The United States
• Canada
• Rest of North America

Regionally, the North American migraine drugs market was the dominating region in the global market in 2023. It is predicted that North America will continue its dominance between 2024 to 2029. According to the American Migraine Association, over 36 million people had migraines in 2015. The migraine drug market in the United States is expected to dominate the North American market during the forecast period and held 65% of the share in 2017. The introduction of Calcitonin gene-related (CGRP) based therapies, growing acquisition of new treatments, and large aided population are expected to drive the market in the United States. In addition, the increasing intake of unhealthy food, increasing incidence of chronic diseases, presence of key players, and escalating concentration on precision medicine in the United States are further estimated to favor the market to grow in the forecast timeframe. 

The U.S. accounted for the majority of the share in the North American region in 2023. Increased consumption of alcohol is one of the major causes that could lead to migraine problems. Nearly 25% of people in America drink alcohol. If the dosage is increased, this may lead to several problems along with migraine. Increasing work stress also leads to migraine disorder. Due to the COVID-19 pandemic, most people work from home for a long time in a day without gaps, which may stress the brain nerves and cause headaches, leading to migraines at certain times.

The Canadian market is expected to showcase a promising CAGR due to the increasing prevalence of migraine. Nearly 3 million people in this region are suffering from migraine. Canada's government has increased campaigns about awareness of migraine disorder and drug use for the relief to lead life happily. An increasing number of product approvals for advanced drugs for this migraine-related problem and increasing healthcare expenditure by a large number of people are the other factors that drive the market forward in Canada. Recently FDA in the US has approved several drugs for the migraine problem, which is accelerating the market growth in Canada.

KEY MARKET PLAYERS

Companies playing a dominant role in the North American migraine drug market profiled in this report are Allergan, GlaxoSmithKline, Pfizer, Endo, and Impax Laboratories. The other prominent vendors in the market include AbbottAeriel BioPharma, Alder Biopharmaceuticals, Amgen, Astellas, Bayer, CoLucid, Eli Lilly, IntelGenx, Ethypharm, Johnson & Johnson, Kowa Pharmaceuticals America, Klaria, Luitpold Pharmaceuticals, AstraZeneca, Meda, Dr. Reddy's Laboratories, OptiNose, Pfizer, Pozen, Eisai, Raptor, RedHill, SUDA, Teva, Aegis Therapeutics, Merck, TG Therapeutics, NValeant, Winston Pharmaceuticals, Allergan, and Zogenix.